Spyre Therapeutics Inc. (SYRE : NASDAQ)
Common Stock
$89.03
USD
+4.31 (5.09%)
Last updated: 2026-09-30
Follow SYRE
SYRE
Spyre Therapeutics Inc.
WealthAwesomePerformance
1 Day
+5.09%
1 Week
+0.98%
1 Month
-0.34%
YTD
+1.76%
Key Statistics
Market Cap
$7.85B
52W High
$110.17
52W Low
$15.86
P/E Ratio
-
50 Day MA
$96.57
200 Day MA
$66.77
Beta
3.00
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/30/2026 | $88.64 | $95.08 | $88.00 | $89.03 | $89.03 | 2,095,889 |
| 9/29/2026 | $85.09 | $86.64 | $83.25 | $84.72 | $84.72 | 1,053,249 |
| 9/28/2026 | $84.72 | $87.12 | $84.00 | $85.79 | $85.79 | 1,045,375 |
| 9/25/2026 | $88.10 | $88.10 | $85.63 | $85.69 | $85.69 | 560,100 |
| 9/24/2026 | $87.46 | $87.46 | $82.93 | $87.09 | $87.09 | 1,729,571 |
| 9/23/2026 | $91.56 | $91.56 | $86.30 | $88.17 | $88.17 | 918,762 |
| 9/22/2026 | $91.53 | $93.58 | $89.90 | $91.97 | $91.97 | 1,223,381 |
| 9/21/2026 | $91.07 | $94.06 | $89.65 | $92.03 | $92.03 | 1,448,750 |
| 9/18/2026 | $92.82 | $93.34 | $89.85 | $90.25 | $90.25 | 3,357,100 |
| 9/17/2026 | $92.86 | $95.19 | $91.14 | $92.68 | $92.68 | 1,394,629 |
Analyst Price Targets
Based on 11 analysts covering SYRE · as of Sep 17, 2026
Wall Street analysts forecast SYRE stock price to rise 34.9% over the next 12 months.
Consensus
Strong Buy4.82 / 5.00
Avg. Target
US$120.08
+34.9% Upside
Current Price
US$89.03
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SYRE's historical volatility
30-Day Vol
50.6%
Annualized
90-Day Vol
62.2%
Annualized
Trend (90d)
-23.8%
Annualized drift
90d Mean
US$81.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$86.54 | US$72.68 – US$103.04 |
| 60 trading days | US$84.12 | US$65.72 – US$107.67 |
| 90 trading days | US$81.76 | US$60.43 – US$110.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-207.82M
- Profit Margin
- 0.00%
- ROE (TTM)
- -22.98%
- EPS (Diluted)
- -1.92
- Book Value
- 10.84
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About SYRE.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NIVF | NewGenIvf Group Limited Class A Ordinary Shares | $0.17 | +133.33% |
| EURKR | Eureka Acquisition Corp Right | $0.41 | +62.14% |
| CMCT | Creative Media & Community Trust Corporation | $2.93 | +52.60% |
| TNON | Tenon Medical Inc | $4.09 | +49.82% |
| AHG | Akso Health Group ADR | $0.90 | +30.25% |
| GRAN | Grande Group Limited Class A Ordinary Shares | $1.09 | +30.13% |
| AIXC | AIxCrypto Holdings, Inc. | $1.31 | +29.70% |
| PACB | Pacific Biosciences of California | $2.37 | +29.51% |
SYRE.US news timeline
1 article covering SYRE.US, most recent first
Latest